海南医学院学报2024，Vol.30Issue(16)：1259-1265,7.DOI:10.13210/j.cnki.jhmu.20231023.004
伏诺拉生联合阿莫西林双联方案根除幽门螺杆菌疗效及安全性的Meta分析
Efficacy and safety of vonoprazan-amoxicillin dual therapy for Helicobacter pylori eradication:A meta-analysis
摘要
Abstract
Objective:To compare the efcacy and safety of Vonoprazan-Amoxicillin(VA)dual therapy versus proton pump in-hibitor(PPI)-based bismuth-containing quadruple therapy(BCQ)in the eradication of Helicobacter(H.)pylori.Methods:We per-formed a systematic search in PubMed,Embase,Cochrane Library,CNKI,and Wanfang databases for relevant clinic trials up to September 2019.The related literatures were analyzed by RevMan 5.4 software.Results:Eleven studies with 3 033 patients were evaluated in this meta-analysis.The H.pylori radication rate of VA dual Therapy was compared with PPI-based quadruple therapy(P＞0.05)by intention-to-treat(ITT)analysis and per-protocol(PP)analysis.The incidence of adverse events in VA dual thera-py was lower than that in PPI-based quadruple therapy[pooled incidence,11.5%vs.25.3%,RR:0.46,95%CI:0.39～0.54,P＜0.001].Subgroup analysis showed that vonoprazan and high-dose amoxicillin(VHA)dual therapy had a higher eradication rate than BCQ(ITT pooledincidence,91.8%vs.82.6%,RR=1.09,95%CI:1.03～1.17,P＜0.05;PP pooled incidence,95.6%vs.86.7%,RR=1.08,95%CI:1.02～1.14,P＜0.05).Conclusions:VA dual therapy can be recommended for H.pylori eradication therapy.关键词
伏诺拉生/幽门螺杆菌/质子泵抑制剂/有效性/安全性/Meta分析Key words
Vonoprazan/Helicobacter pylori/Proton pump inhibitor/Efficacy/Safety/Meta-Analysis分类
医药卫生引用本文复制引用
刘涛,郑盛,杨涓,毛孝周,董赛书,汤胜宇..伏诺拉生联合阿莫西林双联方案根除幽门螺杆菌疗效及安全性的Meta分析[J].海南医学院学报,2024,30(16):1259-1265,7.基金项目
This study was supported by Yunnan Province High Level Health and Family Planning Talent Training Project[Yunwei Kejiao Fa(2017)No.14],Yunnan Provincial Department of Education Science Research Fund Project(No.2023Y1003),and University Joint General Project(2018FH001-080) 云南省高层次卫生计生人才培养工程[云卫科教发(2017)14号] （2017）
云南省教育厅科学研究基金项目(2023Y1003) （2023Y1003）
高校联合面上项目(2018FH001-080) （2018FH001-080）
